Metabasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for chronic diseases involving pathways in the liver. The company provides products primarily for metabolic diseases, such as diabetes, hyperlipidemia, and liver diseases, including hepatitis and primary liver cancer. Its products include Pradefovir, a product candidate for the treatment of hepatitis B that completed phase II clinical trials; CS-917 for the treatment of type 2 diabetes, which is in Phase II clinical trials; MB07133 for the treatment of primary liver cancer that is in Phase I/II clinical trial; and MB07803, for the treatment of type 2 diabetes,...